Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Agios Pharmaceuticals, Inc. (AGIO)

24.75   -0.02 (-0.08%) 09-29 16:00
Open: 24.97 Pre. Close: 24.77
High: 25.12 Low: 24.495
Volume: 417,129 Market Cap: 1,376(M)

Technical analysis

as of: 2023-09-29 4:25:43 PM
Short-term rate:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Mid-term rate:       
Target: Six months: 31.29     One year: 33.27
Support: Support1: 24.04    Support2: 20
Resistance: Resistance1: 26.79    Resistance2: 28.48
Pivot: 25.43
Moving Average: MA(5): 24.56     MA(20): 25.76
MA(100): 26.42     MA(250): 26.52
MACD: MACD(12,26): -0.6     Signal(9): -0.5
Stochastic oscillator: %K(14,3): 17.7     %D(3): 13.9
RSI: RSI(14): 39.2
52-week: High: 31.87  Low: 21.06
Average Vol(K): 3-Month: 344 (K)  10-Days: 280 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ AGIO ] has closed above bottom band by 33.7%. Bollinger Bands are 47.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 25.15 - 25.29 25.29 - 25.42
Low: 24.17 - 24.32 24.32 - 24.46
Close: 24.52 - 24.78 24.78 - 25

Company Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Headline News

Sat, 30 Sep 2023
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CFO Cecilia Jones ... - MarketBeat

Wed, 27 Sep 2023
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF ... - Nasdaq

Mon, 25 Sep 2023
Noteworthy Monday Option Activity: MU, AGIO, AMR - Nasdaq

Wed, 20 Sep 2023
Nordea Investment Management AB Decreases Stock Position in ... - MarketBeat

Tue, 19 Sep 2023
Duality Advisers LP Takes $566000 Position in Agios ... - MarketBeat

Tue, 12 Sep 2023
Armistice Capital LLC Buys 710000 Shares of Agios ... - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 56 (M)
% Held by Insiders 5.168e+007 (%)
% Held by Institutions 1.4 (%)
Shares Short 6,050 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -3.6718e+008
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 859.2
Return on Equity (ttm) -20.1
Qtrly Rev. Growth 2.015e+007
Gross Profit (p.s.) 21.26
Sales Per Share -21.18
EBITDA (p.s.) 1.32e+007
Qtrly Earnings Growth -3.8
Operating Cash Flow 0 (M)
Levered Free Cash Flow -299 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio -0.2
Price to Book value 0
Price to Sales -1.17
Price to Cash Flow 1.35

Stock Dividends

Dividend 0
Forward Dividend 5.9e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.